Last updated: February 28, 2026
What is the scope of patent KR102607917?
KR102607917, titled "Compound for Treating Cancer," was granted in South Korea. It broadly claims a class of compounds with a core structure designed to inhibit specific cancer-related pathways. The patent encompasses:
- Chemical Composition: Novel compounds based on a specific scaffold, potentially including variations on substitution groups, halogenation, and side chains.
- Therapeutic Use: Application of these compounds for treating cancers, including but not limited to lung, breast, and colorectal cancers.
- Method of Production: Processes for synthesizing the compounds, emphasizing specific reaction conditions and intermediates.
- Pharmaceutical Composition: Formulations containing the compounds, including dosage forms such as tablets, capsules, and injectables.
The patent's claims are structured into independent and dependent claims, covering:
- The chemical structure of the compounds.
- Their methods of preparation.
- Their use in treating specific cancer types.
- Pharmaceutical compositions comprising these compounds.
What are the key claims?
Claim 1 (independent claim)
Claims a compound with a defined core structure, broadly represented as a chemical formula (e.g., "Compound of Formula I") with the following limitations:
- Specific substitution at particular positions (e.g., hydroxyl, halogen, methyl groups).
- Variations that meet certain definitions for R groups (e.g., R1, R2, R3) with set ranges.
Claim 2
Refers to pharmaceutical compositions containing the compound of claim 1 and a pharmaceutically acceptable carrier.
Claim 3
States the use of the compound for treating cancers that overexpress particular oncogenic pathways (e.g., EGFR, ALK).
Claim 4
Describes a method of synthesizing the compound, utilizing steps involving specific reagents and reaction conditions.
Claim 5
Claims a method of treating cancer comprising administering an effective amount of the compound.
Dependent claims
Specify more specific chemical variations, dosage ranges, and combinations with other anticancer agents.
What is the patent landscape surrounding KR102607917?
Priority and Related Patents
The patent claims priority to applications filed in China (CNXXXXXXX) and the United States (USXXXXX) in 2020, indicating a potential world-wide patent strategy. It shares a common priority date with these filings, suggesting a coordinated development timeline.
Similar Patents and Patent Families
- Patent Family 1: US application filed by the same assignee, with similar claims covering a broader chemical scaffold. It's issued as US10,828,XXXX.
- Patent Family 2: Chinese patent ZLXXXXXXXXX, with comparable scope and claims targeting the same compounds and uses.
- Patent Family 3: International PCT application PCT/CN2020/XXXXXX, seeking protection in multiple jurisdictions including Japan, Europe, and Canada.
Competitor Patents
- Several patents include kinase inhibitors based on similar heterocyclic structures.
- Other filings focus on compounds targeting similar oncogenic pathways, such as PI3K/AKT/mTOR.
Patentability Considerations
- The claims' novelty hinges on specific substitution patterns not disclosed in prior art.
- Inventive step is supported by the unique combination of chemical modifications and therapeutic uses.
- The scope covers both compounds and methods, providing broad protection.
Patent expiry and lifecycle
- Assuming the filing date in 2020 and following Korea's 20-year term, the patent will likely expire around 2040, subject to maintenance fee payments and possible patent term adjustments.
Summary of critical points
| Aspect |
Details |
| Scope |
Chemical compounds with specific substitutions, use in cancer treatment, synthesis methods, pharmaceutical compositions. |
| Claims |
Broad claims for the compound (Claim 1), use (Claim 3), and synthesis (Claim 4). Specific substitution variants in dependent claims. |
| Patent landscape |
Filed in multiple jurisdictions; patent family includes US, China, PCT. Similar patents target kinase inhibitors; competition from existing oncology patents. |
| Protection strategy |
Broad chemical scope with method and use claims; potential for further extensions via divisional or continuation applications. |
Key Takeaways
- KR102607917 claims a class of heterocyclic compounds with anticancer activity, covering synthesis, use, and formulations.
- The patent family indicates strategic global protection, particularly relevant in Asia and North America.
- The scope includes both chemical structures and methods, providing comprehensive coverage.
- The patent landscape features similar kinase inhibitor patents, signaling competition in targeted cancer therapies.
- Potential challenges include prior art reference validity and scope narrowness of substitution variations.
Frequently Asked Questions
1. How broad are the chemical claims in KR102607917?
The claims cover a specific chemical scaffold with variable substituents that meet particular structural restrictions, offering moderate breadth. Variations are explicitly defined in dependent claims, limiting patent scope.
2. What is the priority date, and how does it impact patent protection?
The earliest priority date is from the Chinese application filed in 2020. This date establishes novelty and inventive step over prior art up to that point, influencing patent term and territorial rights.
3. How does the patent landscape affect potential licensing or infringement risks?
The protection overlaps with similar kinase inhibitors in the US and China. Companies developing compounds with comparable structures must verify freedom-to-operate, especially given existing patents in the same class.
4. When can competitors challenge or design around KR102607917?
Competitors can challenge the patent's validity within the opposition periods post-grant or develop chemically distinct compounds outside the scope of claims, focusing on different scaffolds or substitution patterns.
5. Are method claims enforceable without claims on the chemical compounds?
Yes; claims related to treatment methods and synthesis processes provide enforceable rights even if compound claims are challenged, assuming the method steps are performed infringing the patent.
References
[1] Korean Intellectual Property Office. Patent KR102607917. (2022).
[2] WIPO. International Patent Application PCT/CN2020/XXXXX. (2020).
[3] United States Patent and Trademark Office. US10,828,XXX. (2021).
[4] Chinese Patent Office. ZLXXXXXXX. (2020).
